QualityStocksNewsBreaks Archives - Page 598 of 1387

FridayJul 02, 2021 10:38 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes,” reads a recent article. TumorGenesis, a subsidiary of POAI, has partnered with Swedish cell culture system company Cellevate AB. “The collaboration will involve using TumorGenesis’ expertise in cancer cell culture growth…

FridayJul 02, 2021 10:20 am

QualityStocksNewsBreaks – Brain Scientific Inc.’s (BRSF) Pediatric NeuroCap Is First-of-its-Kind for Pediatric Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is bringing to market new technology that allows EEG testing to be deployed rapidly and accurately in children and adolescents. The Pediatric NeuroCap is intended to solve significant barriers limiting EEG monitoring in pediatric care. “Instead of improvising to make adult-size EEG electrodes fit pediatric patients’ smaller head circumference, Brain Scientific fully adapted its revolutionary NeuroCap to be used in children,” reads a recent article. “The Pediatric NeuroCap comes in two sizes and includes 22 integrated, pre-gelled electrodes compliant with the 10-20 international system. With the…

FridayJul 02, 2021 9:59 am

QualityStocksNewsBreaks – The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Announces the Postponement of FY2021 Earnings Report, Conference Call

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), a producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products sold under the brand names Alkaline88(R), A88 Infused(TM) and A88CBD(TM), announced that the company has not filed its 10-K full-year fiscal year 2021 earnings results. As a result, the company has postponed its earnings call. The company is recognized for its flagship product, Alkaline88, which features an innovative, state-of-the-art proprietary electrolysis process and delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes. The company also offers a line of flavor-infused beverages and a line of CBD-infused products that…

FridayJul 02, 2021 9:26 am

QualityStocksNewsBreaks – Petroteq Energy Inc. ‎‎(TSX.V: PQE) (‎OTC: PQEFF) (FSE: PQCF) Outlines Planned Debt Conversions

Petroteq Energy ‎‎(TSX.V: PQE) (‎OTC: PQEFF) (FSE: PQCF), an integrated oil ‎company focused on the development and implementation of its proprietary oil-‎extraction and remediation technologies, plans to complete debt conversion transactions. According to the announcement, the transactions will involve two arm’s length lenders, to which PQEFF will issue 2,333,176 common shares for $0.094 per share. The transactions will be in satisfaction of $219,318.33, representing both accrued and unpaid interest under previously issued convertible debentures. The company also plans to complete debt conversion transactions with four directors and one former director. Those transactions will involve an additional 862,456 common shares offered…

ThursdayJul 01, 2021 3:21 pm

QualityStocksNewsBreaks – FingerMotion Inc. (FNGR) Leverages Expansion Resolve, Telecom Partnerships to Build Platform

FingerMotion (OTCQX: FNGR) recently released its financial results for the fiscal year ended February 28, 2021, posting “its highest revenue and year-over-year revenue growth thus far.” According to a recent article, the company’s revenue grew by 82% from the previous financial year 2020, reaching $16.68 million. FNGR’s SMS and MMS segment posted business revenue of $6.13 million for the 2021 fiscal year, an 84% growth from the year before. Its gross profit increased by 71%. The company’s overall growth for the 2021 financial year reflected $2.11 million in positive shareholders’ equity. The article continues, “The 2021 impressive fiscal performance was…

ThursdayJul 01, 2021 2:47 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Finalizing Design of Innovative Cancer Visualization Technology

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design of its i/Blue Imaging System(TM), with manufacturing expected to be completed in 2022. The system is an innovative technology designed to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. It solves challenges associated with using blue and white light cystoscopies, which require surgeons to switch back and forth between images and rely on memory to resect. “The company’s advanced technology will show both images simultaneously side-by-side on one screen, providing surgeons with better visualization to remove the cancer and making procedures more efficient,”…

ThursdayJul 01, 2021 1:58 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) UST(TM) Platform Delivers Breakthrough Results Processing One of the Most Powerful Antioxidants Known to Science

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology solutions to the worldwide biotechnology and other industries, today announced the successful application of its Ultra Shear Technology(TM) (“UST(TM)”) platform. According to the update, the novel UST platform was used for the development of more potent formulations of wide-ranging nutraceuticals of high therapeutic value, allowing for more controlled dosing and opportunities for lower cost solutions for both manufacturers and consumers. Specifically, PBI reported breakthrough results in processing one of the most powerful antioxidants known to science, astaxanthin (“AsX”), in…

ThursdayJul 01, 2021 1:36 pm

QualityStocksNewsBreaks – ISW Holdings Inc. (ISWH) Closes on First Phase of Georgia Crypto Mining Farm

ISW Holdings (OTC: ISWH), a global brand management holdings company with commercial operations in telehealth and renewable energy cryptocurrency mining, has finalized a land lease development agreement granting the company full use of a first-phase, seven-acre property in Georgia. The property is designed for cryptocurrency mining operations and includes access to energy resources capable of powering more than 100 MW of cryptocurrency mining capacity. The agreement marks the company’s expansion into hosting mining operations; this first phase consists of more than 20 MW of power being deployed among 20 separate New Generation 1-MW POD5 units. The company also plans to…

ThursdayJul 01, 2021 12:53 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin’s Development

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Among the highlights, the company reported on its continued progress to drive Berubicin towards commercialization for the treatment of glioblastoma multiforme (“GBM”). “In the last 60 days alone, we have achieved fundamental clinical, regulatory and corporate milestones that together demonstrate CNS’ operational, strategic and financial strengths. We are continuously de-risking our Berubicin clinical program by driving development of this truly novel treatment forward as expeditiously as possible. In a…

ThursdayJul 01, 2021 12:36 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Strides in Treatment Innovation Highlighted in New Book

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA”). Years of research have culminated in its main product, the Vivos System, which has been instrumental in treating OSA among adults. In his new book, Pneumopedics and Craniofacial Epigenetics, Vivos Therapeutic’s founder and Chief Medical Officer Dr. G. Dave Singh shares the process behind Vivos System’s innovation and the scientific and biological foundation of the product. “Dr. Singh’s primary goal with this book is to spread…

Site Search

Company Search

Category: QualityStocksNewsBreaks